Clinical Trial Update: SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SHR-1210 alone or with decitabine in relapsed or refractory Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Decitabine (Decitabine)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN